Original Publication Date: 29 May, 2014
Publication / Source: Clinical Investigation
Authors: Camille Serrate, Damien Pouessel, Hélène Gauthier, Christine le Maignan, Luis Teixeira & Stéphane Culine
The microtubule inhibitor vinflunine is currently the only cytotoxic drug approved in Europe for the treatment of patients with metastatic transitional cell carcinoma who failed first-line platinum-based chemotherapy. Indeed, the only Phase III trial ever conducted in this setting demonstrated a benefit in progression-free and overall survival for patients receiving vinflunine plus best supportive care compared with best supportive care alone.